HC Wainwright

Shares of Plug Power Inc (NASDAQ:PLUG) tanked in early trading on Friday, after the company reported a revenue miss for the second quarter. The results came amid an exciting earnings season. Here are some key analyst takeaways. HC Wainwright analyst Amit Dayal maintained a Buy rating and price...

Shares of Cara Therapeutics Inc (NASDAQ:CARA) tanked in early trading on Thursday, with the Dow shedding more than 100 points. The company reported its quarterly results amid an exciting earnings season. Here are some key analyst takeaways. Needham analyst Joseph Stringer downgraded the rating on...

Shares of Coinbase Global Inc (NASDAQ:COIN) tanked in early trading on Friday, despite the company reporting a revenue beat for the first quarter. The results came amid an exciting earnings season. Here are some key analyst takeaways from the release. JPMorgan analyst Kenneth Worthington...

Cryptocurrency platform Coinbase Global (NASDAQ: COIN) is set to report first quarter financial results after market close Thursday. Here is a look at what analysts expect and what could be next for the company. Needham analyst John Todaro has a Buy rating and recently lowered the price target on...

Shares of Coinbase Global Inc (NASDAQ: COIN) were rising on Wednesday, after being under pressure over issues regarding the US Securities and Exchange Commission. Coinbase Global is poised to gain market share in 2023, according to HC Wainwright. The Coinbase Global Analyst: Mike Colonnese...

HC Wainwright initiated coverage of PepGen Inc (NASDAQ: PEPG) with a Buy rating and $26 price target. PepGen is developing next-generation antisense oligonucleotide (ASO) therapeutics for neuromuscular and neurologic diseases. PepGen's lead candidate is PGN-EDO51, a peptide-...

Electric vehicle (EV) equipment provider Blink Charging Co. (NASDAQ: BLNK) reported revenues of $11.5 million, ahead of the consensus estimate of $9.8 million. However, its adjusted loss came in at 41 cents per share, versus Street expectations of a loss of 37 cents a share. Needham On Blink...

InflaRx N.V. (NASDAQ: IFRX) shares are rallying hard Thursday. Here's why.  What Happened: German biopharma InflaRx, which focuses on developing therapies for autoimmune and inflammatory diseases, announced positive data Wednesday from the third cohort of patients in the Phase 2a study...

Plug Power Inc. (NASDAQ: PLUG) announced an acquisition, partnerships, products and updated guidance at its 2021 Plug Symposium. Here's what the Street had to say.  The Plug Power Analysts: RBC Capital Markets analyst Joseph Spak maintained an Outperform rating on Plug Power and...

Contents Field Trip Receives A $20 Price Target With A Buy Rating, Launches New Therapist Programs The DEA Seeks To Increase Federal Production Limits For Research Psilocybin Synthesis Institute Closes $7.25M Series A Funding Through A Non-Traditional VC Path Red Light Holland and...

On Wednesday, HC WainWright began coverage of Field Trip Health (NASDAQ: FTRP), a company in the psychedelics space, which is developing a chain of psychedelics-assisted therapy clinics throughout North America and Europe. The firm gave Field Trip a Buy rating and a $20 price target,...

FibroGen, Inc. (NASDAQ: FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the company's new drug application for roxadustat. The committee is scheduled to meet between 9:30 a.m. and 5:30 p.m. Roxadustat was ...

Regeneron Pharmaceuticals Inc.'s (NASDAQ: REGN) robust pipeline and attractive valuation has prompted an analyst at HC Wainwright to join the bullish camp. The Regeneron Analyst: Analyst Michael King initiated coverage of Regeneron shares with a Buy rating and a $703 price target. The...

The advancements with COVID-19 vaccines of Pfizer Inc. (NYSE: PFE), Moderna Inc. (NASDAQ: MRNA), and AstraZeneca Inc. (NASDAQ: AZN), along with a resurgence of stock market indices like the Dow Jones Industrial Average and S&P 500, hints at a relatively stable...

Amarin Corporation plc (NASDAQ: AMRN) shares were tumbling Tuesday in reaction to a negative verdict issued by a U.S. District Court regarding generic versions of its fish oil pill Vascepa. Amarin shares, which rose to 52-week high of $26.12 in mid-December in reaction to a Vascepa...